Literature DB >> 20579585

Efficacy of bosentan in digital ischemic ulcers.

José A Todoli Parra1, Manuel Miralles Hernández, Manuel A Arrébola López.   

Abstract

Thromboangiitis obliterans (also known as Buerger's disease) is an inflammatory vascular disorder that affects small and medium-sized arteries and veins in the extremities. There is no specific treatment and the only effective intervention is absolute cessation of tobacco use. Endothelial dysfunction appears to be of relevance to this condition and a report has even found that high serum levels of endothelin correlate with the presence of necrosis. We report two cases of digital necrosis showing a very satisfactory response to treatment with bosentan, a dual endothelin receptor antagonist. Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579585     DOI: 10.1016/j.avsg.2010.03.011

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  4 in total

1.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

2.  Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.

Authors:  Joaquin De Haro; Francisco Acin; Silvia Bleda; Cesar Varela; Leticia Esparza
Journal:  BMC Cardiovasc Disord       Date:  2012-02-14       Impact factor: 2.298

Review 3.  Buerger's disease: providing integrated care.

Authors:  Peter Klein-Weigel; Theresa Sophie Volz; Leonora Zange; Jutta Richter
Journal:  J Multidiscip Healthc       Date:  2016-10-12

Review 4.  Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.

Authors:  Javier Narváez; Carmen García-Gómez; Lorenzo Álvarez; Pilar Santo; María Aparicio; María Pascual; Mercè López de Recalde; Helena Borrell; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.